Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its novel multiple sclerosis (MS) therapy, Lucid-MS, toward Phase 2 clinical trials following successful Phase 1 safety and tolerability studies. Unlike conventional MS treatments that primarily target the immune system, Lucid-MS is a patented, first-in-class drug candidate designed to directly protect the myelin sheath damaged by MS. This non-immunomodulatory neuroprotective approach represents a potential paradigm shift in MS treatment.
According to a BioMedWire editorial featuring the company, Lucid-MS has demonstrated the ability to prevent and reverse myelin degradation in preclinical studies, supported by more than a decade of scientific research. The drug candidate is being developed as a disease-modifying therapy that could address the underlying pathology of MS, which involves progressive loss of myelin – the protective coating around nerve fibers. Current MS therapies largely focus on suppressing immune system attacks, but Lucid-MS aims to directly shield and repair the myelin sheath.
Quantum BioPharma is also collaborating with researchers at Massachusetts General Hospital to validate a novel PET imaging technique that may enable direct measurement of myelin integrity in MS patients. If successful, this imaging tool could provide a more precise way to monitor disease progression and treatment response in clinical trials and eventually in clinical practice.
The editorial additionally highlighted developments across the neurological and immune-mediated disease sectors, including programs from Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB), and Clene Inc. (NASDAQ: CLNN). However, Quantum BioPharma's focus on a non-immunomodulatory mechanism sets Lucid-MS apart from many competitors.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of Lucid-MS, which is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models of MS.
The advancement of Lucid-MS into Phase 2 trials is significant because it offers hope for a treatment that could potentially halt or even reverse the damage caused by MS, rather than just managing symptoms. If successful, it could change the standard of care for millions of people living with MS worldwide.
For more information, the full press release can be accessed at https://ibn.fm/iZmx1. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
